BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou H, Wang Y, Lin Y, Cai W, Li X, He X. Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study. Front Oncol 2021;11:774445. [PMID: 34900725 DOI: 10.3389/fonc.2021.774445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Jiang L, Shen Y, Wang Y. Vertical level of blood cell division cycle 42 predicts response and survival benefits to PD-1 inhibitor-based regimen in metastatic colorectal cancer patients. Scand J Clin Lab Invest 2023;:1-8. [PMID: 36811410 DOI: 10.1080/00365513.2023.2175330] [Reference Citation Analysis]
2 Li C, Yu F, Xu W. Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third-line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study. J Clin Pharm Ther 2022;47:2325-34. [PMID: 36495117 DOI: 10.1111/jcpt.13803] [Reference Citation Analysis]
3 Nie C, Lv H, Chen B, Xu W, Wang J, Liu Y, Wang S, Zhao J, He Y, Chen X. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study. Front Oncol 2022;12:917353. [DOI: 10.3389/fonc.2022.917353] [Reference Citation Analysis]